Google DeepMind has launched TxGemma, a collection of AI models tailored to enhance drug discovery and clinical trial predictions. Addressing the slow and costly drug development process, where 90% of candidates fail in early trials, TxGemma utilizes large language models to predict therapeutic properties effectively. It builds on the previous Tx-LLM model, refining its capabilities to provide an open-source platform for researchers. Trained on 7 million examples, TxGemma offers various specialized features, significantly improving efficiency in identifying drug targets and evaluating clinical outcomes through advanced predictive modeling.
AI that explains its own predictions is a game-changer for drug discovery-faster insights mean faster breakthroughs in patient care.
TxGemma seeks to address the challenges of drug development by utilizing large language models to enhance the prediction of therapeutic properties across the entire research pipeline.
Collection
[
|
...
]